Advanced Cell Technology to Host Conference Call to Provide a Corporate Update
August 06 2014 - 4:30PM
Business Wire
Webcast Scheduled for Monday, August 11,
2014 at 5:00 p.m. Eastern Time
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a
leader in the field of regenerative medicine, announced today will
host a conference call on Monday, August 11, 2014 at 5:00 p.m. EDT
during which it will provide a corporate update.
Interested parties may access the call live by dialing (888)
264-3177 and using conference ID 87179264. This event is
also being streamed via webcast. The webcast is available
at http://engage.vevent.com/rt/act~advancedcelltechnology081114.
A replay of the call will also be available via the same link.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a Marlborough, Mass.-based
biotechnology company focused on the development and
commercialization of human embryonic stem cell (hESC) and adult
stem cell technology. The company’s most advanced products are in
clinical trials for the treatment of dry age-related macular
degeneration and Stargardt’s macular degeneration. ACT’s
preclinical programs involve cell therapies for the treatment of
other ocular disorders and for diseases outside the field of
ophthalmology, including autoimmune, inflammatory and wound
healing-related disorders. The company’s intellectual property
portfolio includes pluripotent stem cell platforms – hESC and
induced pluripotent stem cell (iPSC) – and other cell therapy
research programs. For more information,
http://www.advancedcell.com or connect with the Company on
Facebook, Twitter, LinkedIn, Google+, and YouTube.
Forward-Looking Statements
Statements in this news release regarding future financial and
operating results, future growth in research and development
programs, potential applications of our technology, opportunities
for the company and any other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates,” and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including: limited operating history,
need for future capital, risks inherent in the development and
commercialization of potential products, protection of our
intellectual property, and economic conditions generally.
Additional information on potential factors that could affect our
results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on
Form 10-K for the year ended December 31, 2013. Forward-looking
statements are based on the beliefs, opinions, and expectations of
the company’s management at the time they are made, and the company
does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based
on the beliefs, opinions, and expectations of the company’s
management at the time they are made, and the company does not
assume any obligation to update its forward-looking statements if
those beliefs, opinions, expectations, or other circumstances
should change. There can be no assurance that the Company’s
clinical trials will be successful.
Investors:CEOcast, Inc.Bob Woods, 212-732-4300orPress:Russo
PartnersDavid Schull, 858-717-2310